BFS
BBIO icon

Bare Financial Services’s BridgeBio Pharma BBIO Stock Holding History

Bare Financial Services’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.42K Buy
19
+8
+73% +$560 ﹤0.01% 1242
2026
Q1 		$817 Sell
11
-7
-39% -$507 ﹤0.01% 1338
2025
Q4 		$1.38K Buy
18
+7
+64% +$459 ﹤0.01% 1004
2025
Q3 		$571 Buy
+11
New +$536 ﹤0.01% 1213

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Bare Financial Services's BBIO Position: Q2 2026 in Review

Bare Financial Services increased its BridgeBio Pharma (BBIO) stake by 73% in Q2 2026, buying an estimated $560 and bringing the position to 19 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1242.

Bare Financial Services first reported a position in BBIO in Q3 2025 and has held it in 4 quarters since. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Bare Financial Services held 19 shares of BridgeBio Pharma worth $1.42K as of Q2 2026.
  • Bare Financial Services bought 8 BridgeBio Pharma shares in Q2 2026, an estimated $560.
  • BridgeBio Pharma made up ﹤0.01% of Bare Financial Services's portfolio in Q2 2026, its #1242 holding.
  • Bare Financial Services first reported a position in BridgeBio Pharma in Q3 2025 and has held it in 4 quarters since.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Bare Financial Services's 13F filing for Q2 2026, filed 27 Jul 2026.